Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.

Noopur Raje; Shaji Kumar; Teru Hideshima; Kenji Ishitsuka; Dharminder Chauhan; Constantine Mitsiades; Klaus Podar; Steven Le Gouill; Paul Richardson; Nikhil C Munshi

doi:10.1182/blood-2004-06-2281

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.

Identifier:nobleid.org/w1/20260515/58BACE26

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/58BACE26.svg?ark=w1%2F20260515%2F58BACE26)](https://nobleid.org/work/w1/20260515/58BACE26)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Constantine Mitsiades

Claim authorship of this work

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.

Identifier:nobleid.org/w1/20260515/58BACE26

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/58BACE26.svg?ark=w1%2F20260515%2F58BACE26)](https://nobleid.org/work/w1/20260515/58BACE26)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Constantine Mitsiades

Claim authorship of this work